Do you want to read an article? Please log in or register.
Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma
Asthma
Related content
Asthma
Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma
Ann Allergy Asthma Immunol.
Chipps BE, Newbold P, Hirsch I, Trudo F, Goldman M
doi: 10.1016/j.anai.2018.01.030.
RECOMMENDED
Asthma
Relationship Between Benralizumab Exposure and Efficacy for Patients with Severe Eosinophilic Asthma
Clin Pharmacol Ther.
Chia YL, Yan L, Yu B, Wang B, Barker P, Goldman M, Roskos L
doi: 10.1002/cpt.
Asthma
The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies
Curr Med Res Opin.
Goldman M, Hirsch I, Zangrilli JG, Newbold P, Xu X
doi: 10.1080/
RECOMMENDED
Asthma
Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma
Eur Respir J.
Bleecker ER, Wechsler ME, FitzGerald JM, Menzies-Gow A, Wu Y, Hirsch I, Goldman M, Newbold P, Zangrilli JG
doi: 10.1183/13993003.
RECOMMENDED
Asthma
Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial
Lancet Respir Med.
Busse WW, Bleecker ER, FitzGerald JM, Ferguson GT, Barker P, Sproule S, Olsson RF, Martin UJ, Goldman M; BORA study investigators
doi: 10.1016/S2213-2600
Asthma
Efficacy and safety of benralizumab in patients with eosinophilic asthma: a meta-analysis of randomized placebo-controlled trials
Front Med.
Liu T, Wang F, Wang G, Mao H
doi: 10.1007/s11684-017-0565-0.
RECOMMENDED
Asthma
Patient characteristics, biomarkers, and exacerbation risk in severe, uncontrolled asthma
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Eur Respir J
Kraft M, Brusselle G, Mark FitzGerald J, Pavord ID, Keith M, Fagerås M, Garcia Gil E, Hirsch I, Goldman M, Colice G
doi: 10.1183/13993003.00413-2021
RECOMMENDED
Asthma
Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med.
Bernstein JA, Virchow JC, Murphy K, Maspero JF, Jacobs J, Adir Y, Humbert M, Castro M, Marsteller DA, McElhattan J, Hickey L, Garin M, Vanlandingham R, Brusselle G
doi: 10.1016/S2213-2600(19)30372-8.
RECOMMENDED
Asthma
Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison
J Allergy Clin Immunol.
Busse W, Chupp G, Nagase H, Albers FC, Doyle S, Shen Q, Bratton DJ, Gunsoy NB
doi: 10.1016/j.jaci.2018.08.031.